| Literature DB >> 28784993 |
Ahmed S Khairalla1, Reham Wasfi2, Hossam M Ashour3,4.
Abstract
There is limited data on methicillin-resistant Staphylococcus aureus (MRSA) carriage in dental clinics. 1300 specimens from patients, health personnel, and environmental surfaces of a dental clinic in Egypt were tested for MRSA. Antibiotic susceptibility, biofilm formation, Staphylococcal protein A (spa) typing, SCCmec typing, and PCR-based assays were used to detect mecA, mecC, vanA, Panton-Valentine Leukocidin toxin (PVL), and toxic shock syndrome toxin-1 (tst) genes. Among 34 mecA-positive MRSA isolates, five (14.7%) were PVL-positive, seventeen (50%) were tst-positive, ten (29.4%) were vanA-positive, while none harboured mecC. MRSA hand carriage rates in patients, nurses, and dentists were 9.8%, 6.6%, and 5%. The respective nasal colonization rates were 11.1%, 6.7%, and 9.7%. 1.3% of the environmental isolates were MRSA-positive. Strong and moderate biofilm-forming isolates represented 23.5% and 29.4% of MRSA isolates. 24 MRSA isolates (70.6%) were multi-resistant and 18 (52.9%) harboured SCCmec IV. Among eight spa types, t223 (26.5%), t267 (23.5%), and t14339 (23.5%) were predominant. We noted an alarming genetic relatedness between 7 (20.6%) MRSA isolates and the epidemic EMRSA-15 clone, as well as a combined occurrence of tst and PVL in 3 (8.8%) isolates. Results suggest high MRSA pathogenicity in dental wards highlighting the need for more efficient surveillance/infection control strategies.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28784993 PMCID: PMC5547136 DOI: 10.1038/s41598-017-07713-8
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Distribution of the recovered isolates by site of specimen.
| Specimen site | No. (%) of specimens or isolates | |||
|---|---|---|---|---|
| Specimens collected | Recovered isolates | Isolates positive for | Isolates positive for MRSA | |
|
| ||||
| Hand (patients) | 61 (4.69) | 44 (5.10) | 17 (15.18) | 6 (17.65) |
| Nares (patients) | 27 (2.08) | 21 (2.43) | 12 (10.71) | 3 (8.82) |
| Hand (nurses) | 61 (4.69) | 49 (5.68) | 12 (10.71) | 4 (11.76) |
| Nares (nurses) | 30 (2.31) | 26 (3.01) | 11 (9.82) | 2 (5.88) |
| Hand (dentists) | 60 (4.62) | 54 (6.26) | 7 (6.25) | 3 (8.82) |
| Nares (dentists) | 31 (2.38) | 32 (3.71) | 10 (8.93) | 3 (8.82) |
| Total personnel specimens | 270 (20.77) | 226 (26.19) | 69 (61.60) | 21 (61.76) |
|
| ||||
| Clinical-contact surfaces | ||||
| Dental light arm | 66 (5.08) | 10 (1.16) | 5 (4.46) | 1 (2.94) |
| Dentist’s chair | 128 (9.85) | 91 (10.54) | 9 (8.04) | 3 (8.82) |
| Dentist’s drill | 112 (8.62) | 56 (6.49) | 8 (7.14) | 2 (5.88) |
| Dentist’s tool rack | 97 (7.46) | 68 (7.88) | 2 (1.79) | — |
| Patient’s sink faucet | 116 (8.92) | 98 (11.36) | 7 (6.25) | 3 (8.82) |
| X-ray switch | 83 (6.38) | 60 (6.95) | 1 (0.89) | — |
|
| ||||
| Dentist/nurse hand washing sink | 68 (5.23) | 14 (1.62) | 1 (0.89) | — |
| Disinfectant containers | 46 (3.54) | 31 (3.59) | 2 (1.79) | — |
| Door knobs | 93 (7.15) | 72 (8.34) | 3 (2.68) | 3 (8.82) |
| Floors | 75 (5.77) | 44 (5.10) | 2 (1.79) | 1 (2.94) |
| Light switches | 94 (7.23) | 54 (6.26) | 2 (1.79) | — |
| Nurses’ desks | 52 (4.0) | 39 (4.52) | 1 (0.89) | — |
| Total environmental surface specimens | 1030 (79.23) | 637 (73.81) | 43 (38.40) | 13 (38.24) |
A minus sign (−) denotes the absence of an attribute.
Sources and characteristics of individual MRSA isolates (n = 34) in this study.
| Isolate ID | Specimen Source | Dental clinic/ward | Phenotypic resistance profile | Biofilm forming ability | Genotypic characteristics | ||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
| SCC | |||||
|
| |||||||||
| 1a | Hand (patient) | Dental surgery | FOX-OX | Moderate | − | ND | + | t14339 | II |
| 1b | Hand (patient) | Dental surgery | FOX-OX-VAN* | Moderate | − | − | − | t14339 | V |
| 2 | Hand (patient) | Dental surgery | FOX-DO-CN-OX* | Weak | − | ND | − | t267 | I |
| 7 | Hand (patient) | Prosthetic dentistry | FOX-DO-CN-LZD-OX-VAN | Strong | − | + | + | t267 | IV |
| 15 | Hand (patient) | Operative dentistry | FOX-CD-E-CN-LZD-VAN | Moderate | − | + | − | t084 | IV |
| 71 | Hand (patient) | Prosthodontics | FOX-E-OX* | Non | − | ND | − | t223 | I |
| 56 | Nares (patient) | Dental surgery | FOX-C-DO-CN-OX | Moderate | − | ND | − | t267 | IV |
| 63 | Nares (patient) | Prosthetic dentistry | FOX-CIP-CD-CN-LZD-OX-VAN* | Non | − | − | + | t3689 | I |
| 93 | Nares (patient) | Prosthodontics | FOX-E-CN-LZD-OX*-VAN* | Strong | − | − | − | t084 | IV |
| 23 | Hand (nurse) | Dental surgery | FOX-C*-DO-E-CN-OX-VAN* | Weak | − | − | + | t267 | I |
| 112 | Hand (nurse) | Dental surgery | FOX-DO-E-CN-LZD-OX | Non | + | ND | + | t14339 | IV |
| 30 | Hand (nurse) | Prosthetic dentistry | FOX-DO-CN-OX | Weak | − | ND | + | t223 | I |
| 44 | Hand (nurse) | Operative dentistry | FOX-DO-CN-OX-VAN | Moderate | − | + | − | t1339 | IV |
| 58 | Nares (nurse) | Dental surgery | FOX-CIP-CD-E-OX-VAN* | Non | − | − | − | t223 | Non-typeable |
| 59 | Nares (nurse) | Dental surgery | FOX-C-CIP-DO*-E-CN-OX-VAN* | Weak | − | − | + | t14339 | I |
| 111 | Hand (dentist) | Dental surgery | FOX-CD*-DO-CN-OX | Non | + | ND | + | t8506 | IV |
| 109 | Hand (dentist) | Periodontics | FOX-CD-DO-CN-OX-VAN | Non | + | + | − | t380 | IV |
| 95 | Hand (dentist) | Endodontics | FOX-DO-CN-OX | Non | − | ND | − | t267 | IV |
| 65 | Nares (dentist) | Prosthetic dentistry | FOX-CIP-CD-CN-LZD-OX-VAN* | Moderate | − | − | − | t3689 | IV |
| 68 | Nares (dentist) | Operative dentistry | FOX-C*-CD-DO-E-CN-LZD-VAN | Moderate | − | + | − | t380 | I |
| 70 | Nares (dentist) | Periodontics | FOX-C-CD-E-OX* | Non | − | ND | − | t223 | I |
|
| |||||||||
| 5 | Dental light arm | Dental surgery | FOX-CIP-E-CN- OX | Strong | − | ND | + | t223 | IV |
| 11 | Dentist’s chair | Dental surgery | FOX-CD-LZD-VAN | Strong | + | − | + | t14339 | IV |
| 13 | Dentist’s chair | Periodontics | FOX-C*-DO-E-CN-LZD-OX-VAN | Strong | − | + | + | t223 | IV |
| 18 | Dentist’s chair | Prosthetic dentistry | FOX-C*-CD-DO-OX-VAN | Strong | − | − | + | t223 | I |
| 35 | Dentist’s drill | Periodontics | FOX-C-DO-CN-OX*-VAN | Moderate | − | + | + | t084 | IV |
| 42 | Dentist’s drill | Operative dentistry | FOX-DO-E-CN-OX-VAN* | Strong | − | − | + | t267 | IV |
| 25 | Patient’s sink faucet | Prosthetic dentistry | FOX-C*-E-OX*-VAN* | Weak | − | − | + | t14339 | I |
| 26 | Patient’s sink faucet | Prosthetic dentistry | FOX-DO-CN-OX-VAN | Moderate | − | + | − | t223 | I |
| 50 | Patient’s sink faucet | Periodontics | FOX-C*-E-OX-VAN* | Weak | − | − | + | t14339 | I |
| 20 | Door knob | Periodontics | FOX-E-CN-VAN* | Moderate | − | − | + | t267 | IV |
| 33 | Door knob | Operative dentistry | FOX-C*-DO-E-CN-OX-VAN | Strong | − | + | − | t14339 | I |
| 103 | Door knob | Endodontics | FOX-C-DO-E-CN-OX | Non | + | ND | − | t223 | IV |
| 38 | Floor | Operative dentistry | FOX-C-DO-E-CN-OX-VAN* | Weak | − | − | − | t267 | IV |
PVL: The gene encoding the Panton–Valentine leucocidin toxin; vanA: the gene encoding an enzyme that causes a structural change in the terminal amino acid of the pentapeptide chain of peptidoglycan, thus conferring vancomycin resistance; tst: the gene encoding the toxic shock syndrome toxin; spa: staphylococcal protein A; SCCmec: staphylococcal cassette chromosome mec; a plus sign (+) denotes the presence of a gene; a minus sign (−) denotes the absence of a gene; ND: not determined.
FOX: cefoxitin, C: chloramphenicol, CIP: ciprofloxacin, CD: clindamycin, DO: doxycycline, E: erythromycin, CN: gentamicin, LZD: linezolid, OX: oxacillin, and VAN: vancomycin
*Denotes intermediate resistance to the antibiotic, according to CLSI guidelines and breakpoints[88].
The isolates were classified as biofilm non producers, weak, moderate, and strong biofilm producers based on previously published criteria[34].
All the MRSA isolates investigated in the current study were mecA-positive and mecC-negative.
The spa types shown are based on the Ridom StaphType software.
Non-typeable: An isolate that was positive only for the mecA gene, with no PCR product obtained, or not in agreement with the predicted band patterns of SCCmec types I-V by the multiplex PCR method used.
Ward distribution of the specimens collected in this study.
| Dental ward | No. (%) of specimens or isolates | |||||
|---|---|---|---|---|---|---|
|
|
|
| ||||
| Specimens collected | Recovered isolates | Specimens collected | Recovered isolates | Specimens collected | Recovered isolates | |
| Endodontics | 38 (14.02) | 32 (14.16) | 167 (16.21) | 126 (19.78) | 205 (15.77) | 158 (18.31) |
| Operative dentistry | 40 (14.81) | 26 (11.51) | 165 (16.02) | 104 (16.33) | 205 (15.77) | 130 (15.06) |
| Periodontics | 45 (16.7) | 28 (12.39) | 210 (20.39) | 103 (16.17) | 255 (19.62) | 131 (15.18) |
| Prosthetic dentistry | 49 (18.15) | 48 (21.24) | 131 (12.72) | 90 (14.13) | 180 (13.85) | 138 (15.99) |
| Prosthodontics | 48 (17.8) | 46 (20.35) | 152 (14.76) | 118 (18.52) | 200 (15.38) | 164 (19.00) |
| Dental surgery | 50 (18.52) | 46 (20.35) | 205 (19.90) | 96 (15.07) | 255 (19.61) | 142 (16.46) |
| Total | 270 (100) | 226 (100) | 1030 (100) | 637 (100) | 1300 (100) | 863 (100) |
Frequencies, geographical spread, repeat successions, and predicted clonal complexes (CCs) of the spa types detected in this study.
| Cluster group and | Ridom | No. (%) of MRSA isolates | Geographical spread* |
| Predicted MLST CC | |||
|---|---|---|---|---|---|---|---|---|
| Total specimens | Personnel specimens | Environmental surface specimens | Relative global frequency* | |||||
| Cluster 1 | t223 | 9 (26.5%) | 4 (19%) | 5 (38.5%) | 0.42% | Austria, Belgium, Chile, Czech Republic, Denmark, Detmold, France, Germany, Iceland, Ireland, Israel, Italy, Jordan, Minden, Netherlands, New Zealand, Norway, Romania, Spain, Sweden, Switzerland, Syria, United Arab Emirates, United Kingdom, the Gaza Strip (Palestine)[ | 26-23-13-23-05-17-25-17-25-16-28 | CC22 |
| t14339 | 8 (23.5%) | 4 (19%) | 4 (30.8%) | 0.00% | Ireland | 26-23-13-23-36-17-25-17-25-16-28 | CC22 | |
| t3689 | 2 (5.9%) | 2 (9.5%) | — | 0.00% | Denmark | 26-23-13-23-05-17-25-17-25-25–16-28 | CC22 | |
| t8506 | 1 (2.9%) | 1 (4.8%) | — | 0.00% | Saudi Arabia | 26-23-13-16-05-17-25-17-25-16-28 | CC22 | |
| Singletons | t267 | 8 (23.5%) | 5 (23.8%) | 3 (23%) | 0.30% | Argentina, Austria, Belgium, Cyprus, Denmark, France, Gabon, Germany, Iceland, Iran, Israel, Italy, Jordan, Lebanon, Netherlands, New Zealand, Norway, Saudi Arabia, South Africa, Spain, Sweden, Taiwan, United Arab Emirates, United Kingdom, United States | 07-23-12-21-17-34-34-34-33-34 | CC80 |
| t084 | 3 (8.9%) | 2 (9.5%) | 1 (7.7%) | 1.76% | Argentina, Australia, Austria, Belgium, China, Denmark, Finland, France, Gabon, Germany, Greece, Iceland, Indonesia, Iran, Italy, Jordan, Lebanon, Netherlands, New Zealand, Nigeria, Norway, Poland, Romania, South Africa, Spain, Sweden, Switzerland, Taiwan, Uganda, United Arab Emirates, United Kingdom, United States, Germany | 07-23-12-34-34-12-12-23-02-12-23 | CC15 | |
| t1339 | 1 (2.9%) | 1 (4.8%) | — | 0.01% | Austria, Denmark, Germany, Iceland, Norway, Sweden, United Arab Emirates | 07-12-21-17-13-13-34-13-34-33-34 | CC80 | |
| Excluded | t380 | 2 (5.9%) | 2 (9.5%) | — | 0.00% | Germany, Lebanon, Sweden, United Kingdom | 26-34-33-34 | NP |
*Based on data from the Ridom StaphType database (http://spa.ridom.de/frequencies.shtml), last accessed on 15 November 2016, unless otherwise stated. Countries from the Arab world are double-underlined.
a spa-CC: denotes spa clonal complex as determined by the Based Upon Repeat Pattern (BURP) algorithm in the Ridom StaphType software with a distance cost of ≤ 5; excluded: denotes entries excluded from BURP clustering because the spa repeat pattern comprised fewer than five repeats.
bNomenclature according to Harmsen et al.[91]; the spa types shown are based on the Ridom StaphType software.
cA minus sign (−) indicates the absence of the spa type.
MLST CC: denotes predicted clonal complexes based on multi-locus sequence typing.
According to the Ridom SpaServer (http://spaserver.ridom.de).
Based on data from[98].
Based on data from[99].
NP: not predictable (not yet assigned to CC).
Characteristics and detailed distribution of the spa-CCs and spa-types detected in this study.
| Cluster group and | Ridom | No. of MRSA isolates | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
| |||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| Non ( | Weak ( | Mode-rate ( | Strong ( | ||||||||||||
|
|
|
|
|
| ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||||
| Cluster 1 |
| 1 | 0 | 1 | 1 | — | 1 | 1 | 2 | — | 1 | 1 | — | 1 | — | 2 | 3 | 1 | 2 | 1 | 2 | 4 | 4 | 1 | 1 | 3 |
|
| 2 | — | 1 | 1 | — | — | — | 1 | — | 2 | 1 | — | — | 1 | 1 | 1 | — | 5 | 2 | 2 | 6 | 1 | 3 | 2 | 2 | |
|
| — | 1 | — | — | — | 1 | — | — | — | — | — | — | — | — | — | 2 | — | — | — | — | 1 | 1 | — | 1 | — | |
|
| — | — | — | — | 1 | — | — | — | — | — | — | — | — | — | — | — | — | 1 | 1 | — | 1 | 1 | — | — | — | |
| Singletons |
| 2 | 1 | 1 | — | 1 | — | — | — | 1 | — | 1 | 1 | 1 | 2 | 1 | 1 | — | 3 | — | 1 | 4 | 1 | 3 | 2 | 2 |
|
| 1 | 1 | — | — | — | — | — | — | 1 | — | — | — | — | 1 | 1 | — | 1 | — | — | 2 | 1 | — | — | 2 | 1 | |
|
| — | — | 1 | — | — | — | — | — | — | — | — | — | — | 1 | — | — | — | — | — | 1 | — | — | — | 1 | — | |
| Excluded |
| — | — | — | — | 1 | 1 | — | — | — | — | — | — | — | 1 | 1 | — | — | — | 1 | 2 | — | 1 | — | 1 | — |
spa-CC: denotes spa clonal complex as determined by the Based Upon Repeat Pattern (BURP) algorithm in the Ridom StaphType software with a distance cost of ≤ 5; excluded: denotes entries excluded from BURP clustering because the spa repeat pattern comprised fewer than five repeats; D light arm: Dental light arm; D chair: Dentist’s chair; D drill: Dentist’s drill; P sink faucet: Patient’s sink faucet; PVL: The gene encoding the Panton–Valentine leucocidin toxin; vanA: the gene encoding an enzyme that causes a structural change in the terminal amino acid of the pentapeptide chain of peptidoglycan, thus conferring vancomycin resistance; tst: the gene encoding the toxic shock syndrome toxin; spa: staphylococcal protein A; a minus sign (−) denotes the absence of an attribute.
Nomenclature according to Harmsen et al.[91]; the spa types shown are based on the Ridom StaphType software.
All the MRSA isolates investigated in the current study were mecA-positive and mecC-negative.
The isolates were classified as biofilm non-producers, weak, moderate, and strong biofilm producers based on previously published criteria[34].
Figure 1Population structure of the tested MRSA isolates (n = 34) based on BURP analysis. This analysis was performed using the Based Upon Repeat Pattern (BURP) algorithm of the Ridom StaphType software (Ridom GmbH, Würzburg, Germany) at a cost setting of ≤ 5 and excluding spa-types with 5 or fewer repeats. Each dot represents a different spa type, with the diameter of the dot being proportional to the quantity of the corresponding spa type. Clusters of linked spa types correspond to spa clonal complexes (spa-CCs). The predict founder of a cluster (which was used for defining the cluster) is shown in blue, while the others in black. Near the lines of connection, the mutations involved in the transition from a spa type to the next one are reported in detail. All DNA changes are meant to occur from the founder to the periphery. Legend: numbers along the lines refer to the repeat sequence involved in the mutation; +indicates the acquisition of a repeat sequence; - indicates the loss of a repeat sequence; within circles the numbers of the strains of each CC appear between brackets. In summary, the analysis identified a single clonal complex (spa-CC223) comprising spa types t223, t14339, t3689, and t8506; n = 20 isolates, and accounted for 58.8% of all tested MRSA isolates, as well as 3 singletons (t267, t084, and t1339; n = 12 isolates, 35.2%), while excluded 2 isolates (t380, 5.8%) from the clustering, as they consisted of four repeat units only.
Characteristics and detailed distribution of the SCCmec types detected in this study.
| SCC | No. of MRSA isolates | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
| ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| Non ( | Weak ( | Moderate ( | Strong( | |||||||||||
|
|
|
|
|
| |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||||
| I | 2 | 1 | 2 | 1 | — | 2 | — | 1 | — | 3 | 1 | — | — | 2 | 2 | 5 | 1 | 3 | — | 3 | 7 | 3 | 6 | 2 | 2 |
| II | 1 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1 | — | — | 1 | — | — | 1 | — |
| III | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| IV | 2 | 2 | 2 | — | 3 | 1 | 1 | 2 | 2 | — | 2 | 1 | 2 | 4 | 4 | 2 | 1 | 5 | 5 | 7 | 9 | 5 | 1 | 6 | 6 |
| V | 1 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1 | — | — | — | — | — | 1 | — |
| Non-typeable | — | — | — | 1 | — | — | — | — | — | — | — | — | — | — | — | — | — | 1 | — | — | — | — | — | — | — |
SCCmec: staphylococcal cassette chromosome mec; Non-typeable: an isolate with no PCR product obtained, or not in agreement with the predicted band patterns of SCCmec types I-V by the multiplex PCR method used; D light arm: Dental light arm; D chair: Dentist’s chair; D drill: Dentist’s drill; P sink faucet: Patient’s sink faucet; PVL: The gene encoding the Panton–Valentine leucocidin toxin; vanA: the gene encoding an enzyme that causes a structural change in the terminal amino acid of the pentapeptide chain of peptidoglycan, thus conferring vancomycin resistance; tst: the gene encoding the toxic shock syndrome toxin; spa: staphylococcal protein A; a minus sign (−) denotes the absence of an attribute.
All the MRSA isolates investigated in the current study were mecA-positive and mecC-negative.
The isolates were classified as biofilm non-producers, weak, moderate, and strong biofilm producers based on previously published criteria[34].
Antimicrobial resistance rates among the investigated MRSA isolates in relation to different clonal lineages.
| Antimicrobial agent | No. (%) of MRSA isolates phenotypically resistant to |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
| |||||||
| t223 | t14339 | t3689 | t8506 | t267 | t084 | t1339 | t380 |
| ||
| Cefoxitin (FOX) | 8 (88.9%) | 8 (100%) | 2 (100%) | 1 (100%) | 8 (100%) | 3 (100%) | 1 (100%) | 1 (50%) | 32 (94.1%) | 0.259 |
| Chloramphenicol (C) | 2 (22.2%) | 1 (12.5%) | 0 | 0 (0%) | 2 (25%) | 1 (33.3%) | 0 | 0 | 6 (17.6%) | 0.937 |
| Ciprofloxacin (CIP) | 2 (22.2%) | 1 (12.5%) | 2 (100%) | 0 (0%) | 0 | 0 | 0 | 0 | 5 (14.7%) |
|
| Clindamycin (CD) | 3 (33.3%) | 1 (12.5%) | 2 (100%) | 0 (0%) | 0 | 1 (33.3%) | 0 | 2 (100%) | 9 (26.5%) |
|
| Doxycycline (DO) | 5 (55.6%) | 2 (25%) | 0 | 1 (100%) | 7 (87.5%) | 1 (33.3%) | 1 (100%) | 2 (100%) | 19 (55.9%) | 0.081 |
| Erythromycin (E) | 6 (66.7%) | 5 (62.5%) | 0 | 0 | 4 (50%) | 2 (66.7%) | 0 | 1 (50%) | 18 (52.9%) | 0.571 |
| Gentamicin (CN) | 5 (55.6%) | 3 (37.5%) | 2 (100%) | 1 (100%) | 8 (100%) | 3 (100%) | 1 (100%) | 2 (100%) | 25 (73.5%) | 0.073 |
| Linezolid (LZD) | 1 (11.1%) | 2 (25%) | 2 (100%) | 0 | 1 (12.5%) | 2 (66.7%) | 0 (0%) | 1 (50%) | 9 (26.5%) | 0.129 |
| Oxacillin (OX) | 7 (77.8%) | 6 (75%) | 2 (100%) | 1 (100%) | 6 (75%) | 0 | 1 (100%) | 1 (50%) | 24 (70.6%) | 0.209 |
| Vancomycin (VAN) | 3 (33.3%) | 2 (25%) | 0 | 0 | 1 (12.5%) | 2 (66.7%) | 1 (100%) | 2 (100%) | 11 (32.4%) | 0.140 |
Data indicate the number and percentage (%) of full resistance for each respective antimicrobial agent; isolates showing intermediate resistance to the tested antimicrobials are not included in the table.
All the tested isolates were susceptible to cefaclor, ceftriaxone, imipenem, and neomycin.
spa-CC: denotes spa clonal complex as determined by the Based Upon Repeat Pattern (BURP) algorithm in the Ridom StaphType software with a distance cost of ≤ 5; excluded: denotes entries excluded from BURP clustering because the spa repeat pattern comprised fewer than five repeats.
P values calculated using chi-squared tests of 2 × 8 contingency tables. P values < 0.05 are highlighted in bold.
Figure 2Biofilm-forming abilities of the tested MRSA isolates in relation to the specimen source.
PCR primers used in this study.
| Target gene (Primer specificity) | Primer sequence (5’ → 3’ direction) | Amplicon size (bp) | Annealing temperature (°C) | Reference |
|---|---|---|---|---|
|
| Forward: GAAGATGGCTATCGTGTCACA Reverse: GGAACTTGTTGAGCAGAGGTT | 307 | 52 | Current study |
|
| Forward: GGGTTCAGCCAGATTCATTTGT Reverse: GTACTGTTGCTTCGTTCAATGG | 138 | 52 | Current study |
|
| 1113_ Forward: TAAAGACGATCCTTCGGTGAGC 1514_ Reverse: CAGCAGTAGTGCCGTTTGCTT | Variable (180–670) | 52 |
|
|
| Forward: GCTGGACAAAACTTCTTGGAATAT Reverse: GATAGGACACCAATAAATTCTGGATTG | 83 | 50 |
|
|
| Forward: GGGAAAACGACAATTGC Reverse: GTACAATGCGGCCGTTA | 732 | 50 |
|
| SCC | CIF2 F2: TTCGAGTTGCTGATGAAGAAGG CIF2 R2: ATTTACCACAAGGACTACCAGC | 495 | 47 |
|
| SCC | KDP F1: AATCATCTGCCATTGGTGATGC KDP R1: CGAATGAAGTGAAAGAAAGTGG | 284 | 47 |
|
| SCC | RIF5 F10: TTCTTAAGTACACGCTGAATCG RIF5 R13: GTCACAGTAATTCCATCAATGC | 414 | 47 |
|
| SCC | DCS F2: CATCCTATGATAGCTTGGTC DCS R1: CTAAATCATAGCCATGACCG | 342 | 47 |
|
| SCC | ccrC F2: GTACTCGTTACAATGTTTGG ccrC R2: ATAATGGCTTCATGCTTACC | 449 | 47 |
|
|
| Forward: ACCCCTGTTCCCTTATCATC Reverse: TTTTCAGTATTTGTAACGCC | 326 | 47 |
|
*F: forward primer; R: reverse primer.